No Data
No Data
SmartHK shareholder equity disclosure | July 22nd
HK shareholders' equity disclosure | July 22nd
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Tracking Hong Kong stocks | Rise of domestic cosmetics in the market, institutions are bullish on top companies' penetration rate improvement (attached concept stocks).
Cosmetics lead the domestic industry growth, with market share continuing to rise.
Kintor Pharmaceutical Releases Anti-Hair Loss Product; Shares Up 8%
Kaituo Pharmaceuticals-B (09939.HK): Sales of cosmetics containing KX-826 as the core component have been launched.
On July 10th, Glad Tidings Pharmaceutical - B (09939.HK) announced that its self-developed KX-826 has been given an International Nomenclature of Cosmetic Ingredients ("INCI") name. The company's cosmetic products, with KX-826 as the main ingredient, have been officially launched and sold globally recently. The first product is an external anti-hair loss solution ("new product") for androgenetic alopecia ("AGA"). The group will further explore the efficacy of KX-826 in the treatment of AGA and acne, actively enrich the product line, and increase promotion to target users to meet the needs of different usage scenarios. The company believes that the new...
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
No Data